Clinical Trials
28 trialsNCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT00412022 2023-03-24
HOBOE
National Cancer Institute, Naples
Phase 3 Unknown
NCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT05164952 2021-12-21
Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
Assiut University
Phase 3 Unknown
NCT00127205 2021-07-02
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
SWOG Cancer Research Network
Phase 3 Completed
NCT01099436 2020-01-21
NEO-ZOTAC
Borstkanker Onderzoek Groep
Phase 3 Completed
NCT00130494 2019-04-16
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Spanish Breast Cancer Research Group
Phase 3 Terminated
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00107263 2016-12-06
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00022087 2016-07-19
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00202059 2015-12-16
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
HealthPartners Institute
Phase 3 Completed
NCT00375505 2015-09-07
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
Novartis
Phase 3 Completed
NCT00512993 2015-03-05
NATAN
GBG Forschungs GmbH
Phase 3 Completed
NCT00320710 2014-08-22
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Novartis
Phase 3 Completed
NCT00712985 2014-04-24
CTIBL
Milton S. Hershey Medical Center
Phase 3 Completed
NCT00050011 2014-03-21
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Novartis
Phase 3 Completed
NCT00049452 2014-01-06
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00301886 2013-11-13
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
Phase 3 Withdrawn
NCT00072020 2013-08-02
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00326820 2013-03-13
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Wales Cancer Trials Unit
Phase 3 Unknown
NCT00171340 2012-04-16
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Novartis
Phase 3 Completed
NCT00171314 2012-04-11
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Novartis
Phase 3 Completed
NCT00375427 2012-04-11
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Novartis
Phase 3 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed
NCT00376740 2011-08-23
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
Soroka University Medical Center
Phase 3 Completed
NCT00372710 2009-11-23
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Novartis
Phase 3 Terminated